Tolerability and pharmacokinetics of leritrelvir in Chinese participants with severe renal impairment and healthy matched control subjects
Modest PK alterations in severe renal impairment are clinically insignificant given leritrelvir's wide therapeutic index. The drug is well-tolerated (mild-to-moderate, short-duration AEs), and no dose adjustment is needed for patients with renal impairment.
Authors
- Ziyi Zhou (ORCID: https://orcid.org/0000-0002-9775-3839)
- Hui Li (ORCID: https://orcid.org/0000-0001-9198-3951)
- Xiao‐Qing Wen
- Xi Luo (ORCID: https://orcid.org/0000-0002-5051-2659)
- Yue‐Yuan Huang
- Wen‐rui Zhang
- J I‐yi Huang
- You‐yun Li
Institutions
- Central South University (CN)
- China Pharmaceutical University (CN)
- Changsha Medical University (CN)
- First Affiliated Hospital of Xiamen University (CN)
- RayBiotech (China) (CN)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1002/bcp.70474
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00